NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC) · Locally Advanced and Metastatic Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

West China Hospital, Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Kexun Zhou, Dr.) · kexunzhou@wchscu.cn · +028 85423609

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC

Abroad (travel likely)RecruitingPHASE3

Tampa, United States · Atlanta, United States

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE3

Los Angeles, United States · Los Angeles, United States

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Pancreatic Cancer · Pancreatic Ductal Adenocarcinoma · PDAC

Abroad (travel likely)RecruitingEARLY_PHASE1

Boston, United States · Boston, United States

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma · Borderline Resectable Pancreatic Adenocarcinoma · Locally Advanced Pancreatic Adenocarcinoma

Abroad (travel likely)RecruitingPHASE1

Newport Beach, United States · Detroit, United States